Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-Ribose Polymerase inhibitors and low-dose alkylating chemotherapy. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-Ribose Polymerase inhibitors and low-dose alkylating chemotherapy

In this study, we evaluated novel treatment approaches in newly generated models of FH- and SDHB-deficient RCC. CRISPR/Cas9 was used to engineer isogenic Fh1- and Sdhb-deficient murine models of RCC. RNA-Seq was used to profile this model. Overall design: RNA-Seq was performed on RENCA parental cells in comparison to FH1 & SDHB knockout cells. Two biological replicates were performed for each cell line.